SCHEMBL173201

SCHEMBL173201

Cc1cnnn1O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9946498 0.67
SCHEMBL98990 0.67
SCHEMBL437712 0.67
SCHEMBL19018527 0.67
SCHEMBL12533290 0.67
SCHEMBL23928715 0.67
SCHEMBL9596247 0.67
SCHEMBL23928718 0.65
SCHEMBL2937685 0.63 TSHR (0.32)
SCHEMBL3072438 0.63

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023225320-A1 EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF NOVARTIS AG (CH) 2023-11-23 WO disclosed
EP-3842420-B1 HETEROARYL INHIBITORS OF PDE4 TETRA DISCOVERY PARTNERS LLC (US) 2022-12-07 EP disclosed
US-20210323960-A1 FUSED TRI-CYCLIC COMPOUND AS PDE3/PDE4 DUAL INHIBITOR CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2021-10-21 US disclosed
EP-3865576-A1 LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS Dicerna Pharmaceuticals, Inc. (US) 2021-08-18 EP disclosed
EP-3842420-A1 HETEROARYL INHIBITORS OF PDE4 Tetra Discovery Partners LLC (US) 2021-06-30 EP disclosed
EP-3822272-A1 FUSED TRI-CYCLIC COMPOUND AS PDE3/PDE4 DUAL INHIBITOR Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) 2021-05-19 EP disclosed
US-20200275653-A1 INDUCTION OF A PHYSIOLOGICAL DISPERSION RESPONSE IN BACTERIAL CELLS IN A BIOFILM UNIV NEW YORK STATE RES FOUND (US) 2020-09-03 US disclosed
US-10653140-B2 Induction of a physiological dispersion response in bacterial cells in a biofilm THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2020-05-19 US disclosed
US-20200031862-A1 LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS DICERNA PHARMACEUTICALS, INC. 2020-01-30 US disclosed
WO-2020011254-A1 FUSED TRI-CYCLIC COMPOUND AS PDE3/PDE4 DUAL INHIBITOR 正大天晴药业集团股份有限公司 2020-01-16 WO disclosed
US-20080161546-A1 Glycomimetic replacements for hexoses and N-acetyl hexosamines GLYCOMIMETICS, INC. (US) 2008-07-03 US disclosed
US-20080161546-A1 Glycomimetic replacements for hexoses and N-acetyl hexosamines GLYCOMIMETICS, INC. (US) 2008-07-03 US disclosed
WO-2008060378-A2 GLYCOMIMETIC REPLACEMENTS FOR HEXOSES AND N-ACETYL HEXOSAMINES GLYCOMIMETICS, INC. (US) 2008-05-22 WO disclosed
US-20080058397-A1 5-(3-(3-(4-hexanoylphenyl)-2,5-dioxoimidazolidin-4-yl)propyl)thiophene-2-carboxylic acid; prostaglandin agonist; ocular hypotensive agent; post-sergical and post-laser trabeculectomy ocular hypertensive episodes, glaucoma, and as presurgical adjuncts OLD DAVID W 2008-03-06 US disclosed
US-20080051374-A1 Therapeutic Amides and related Compounds ALLERGAN, INC. 2008-02-28 US disclosed
US-20080045576-A1 THERAPEUTIC N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES ALLERGAN, INC. 2008-02-21 US disclosed
US-20070293561-A1 5-{3-[(1S,5S)-5-(3-Chloro-5-hydroxymethyl-phenoxymethyl)-4-oxo-cyclopent-2-enyl]-propyl}-thiophene-2-carboxylic acid; Treating eye diseases including glaucoma or ocular hypertension; selective prostaglandin EP2 agonists ALLERGAN, INC. 2007-12-20 US disclosed
US-20070281981-A1 Glaucoma; 3-substituted pyrrolidine compounds; prostaglandin receptor modulators ALLERGAN, INC. 2007-12-06 US disclosed
US-20070270387-A1 THERAPEUTIC CYCLOPENTANE DERIVATIVES ALLERGAN, INC 2007-11-22 US disclosed
US-20070259836-A1 THERAPEUTIC CYCLOPENTANE DERIVATIVES ALLERGAN, INC. 2007-11-08 US disclosed